Zevra Therapeutics Inc Financials

ZVRA

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Zevra Therapeutics Inc (ZVRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 27/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Zevra Therapeutics Inc has an operating margin of -368.5%, meaning the company retains $-368 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -180.6% the prior year.

Growth

Zevra Therapeutics Inc's revenue declined 14% year-over-year, from $27.5M to $23.6M. This contraction results in a growth score of 0/100.

Leverage

Zevra Therapeutics Inc has a moderate D/E ratio of 1.50. This balance of debt and equity financing earns a leverage score of 56/100.

Liquidity

With a current ratio of 2.53, Zevra Therapeutics Inc holds $2.53 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 81/100.

Cash Flow

While Zevra Therapeutics Inc generated -$69.7M in operating cash flow, capex of $0 consumed most of it, leaving -$69.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

2/9

Zevra Therapeutics Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.66x

For every $1 of reported earnings, Zevra Therapeutics Inc generates $0.66 in operating cash flow (-$69.7M OCF vs -$105.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-11.8x

Zevra Therapeutics Inc earns $-11.8 in operating income for every $1 of interest expense (-$87.0M vs $7.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

$23.6M

YoY-14.0%

5Y CAGR+13.0%

Zevra Therapeutics Inc generated $23.6M in revenue in fiscal year 2024. This represents a decrease of 14.0% from the prior year.

EBITDA

-$80.6M

YoY-65.9%

Zevra Therapeutics Inc's EBITDA was -$80.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 65.9% from the prior year.

Free Cash Flow

-$69.7M

YoY-105.9%

Zevra Therapeutics Inc generated -$69.7M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 105.9% from the prior year.

Net Income

-$105.5M

YoY-129.1%

Zevra Therapeutics Inc reported -$105.5M in net income in fiscal year 2024. This represents a decrease of 129.1% from the prior year.

EPS (Diluted)

N/A

Cash & Debt

$33.8M

YoY-21.5%

5Y CAGR+60.0%

10Y CAGR+12.7%

Zevra Therapeutics Inc held $33.8M in cash against $59.5M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

54M

YoY+29.2%

Zevra Therapeutics Inc had 54M shares outstanding in fiscal year 2024. This represents an increase of 29.2% from the prior year.

Gross Margin

68.6%

YoY-20.7pp

5Y CAGR+46.5pp

Zevra Therapeutics Inc's gross margin was 68.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 20.7 percentage points from the prior year.

Operating Margin

-368.5%

YoY-187.8pp

5Y CAGR-210.1pp

Zevra Therapeutics Inc's operating margin was -368.5% in fiscal year 2024, reflecting core business profitability. This is down 187.8 percentage points from the prior year.

Net Margin

-446.8%

YoY-279.2pp

5Y CAGR-255.8pp

Zevra Therapeutics Inc's net profit margin was -446.8% in fiscal year 2024, showing the share of revenue converted to profit. This is down 279.2 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$42.1M

YoY+5.8%

5Y CAGR+16.7%

10Y CAGR+13.5%

Zevra Therapeutics Inc invested $42.1M in research and development in fiscal year 2024. This represents an increase of 5.8% from the prior year.

Share Buybacks

YoY-100.0%

Zevra Therapeutics Inc spent $0 on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.

Capital Expenditures

YoY-100.0%

Zevra Therapeutics Inc invested $0 in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

ZVRA Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$23.6M-14.0%	$27.5M+170.3%	$10.2M-64.5%	$28.6M+115.6%	$13.3M+3.5%	$12.8M
Cost of Revenue	$7.4M+151.9%	$2.9M+1226.6%	$222K-89.2%	$2.1M	N/A	$10.0M
Gross Profit	$16.2M-33.9%	$24.5M+146.7%	$9.9M-62.6%	$26.6M	N/A	$2.8M
R&D Expenses	$42.1M+5.8%	$39.8M+101.0%	$19.8M+94.9%	$10.2M+14.9%	$8.8M-54.5%	$19.4M
SG&A Expenses	$54.9M+59.9%	$34.3M+128.2%	$15.0M+72.8%	$8.7M+9.8%	$7.9M-26.8%	$10.8M
Operating Income	-$87.0M-75.4%	-$49.6M-16.5%	-$42.6M-650.7%	$7.7M+237.8%	-$5.6M+72.4%	-$20.3M
Interest Expense	$7.4M+389.7%	$1.5M+348.1%	$335K+48.2%	$226K-95.3%	$4.8M-1.5%	$4.9M
Income Tax	$15.4M	$0+100.0%	-$33K-197.1%	$34K+200.0%	-$34K-54.5%	-$22K
Net Income	-$105.5M-129.1%	-$46.0M-72.0%	-$26.8M-212.9%	-$8.6M+33.0%	-$12.8M+48.0%	-$24.5M
EPS (Diluted)	N/A	N/A	N/A	$-2.11	$-3.21	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$26.1M+0.7%	$25.9M+26.9%	$20.4M+69.4%	$12.0M+170.7%	$4.4M+29.9%	$3.4M-73.5%	$12.9M+346.3%	$2.9M
Cost of Revenue	$1.2M-90.0%	$12.4M+820.4%	$1.3M-1.5%	$1.4M-61.8%	$3.6M+1941.7%	$175K-91.2%	$2.0M+1288.2%	$144K
Gross Profit	$24.8M+83.9%	$13.5M-29.1%	$19.1M+78.5%	$10.7M+1118.8%	$876K-73.0%	$3.3M-70.2%	$10.9M+297.0%	$2.8M
R&D Expenses	$3.4M0.0%	$3.4M+5.4%	$3.3M-61.0%	$8.4M-20.6%	$10.5M-14.3%	$12.3M+7.5%	$11.4M-7.1%	$12.3M
SG&A Expenses	$16.9M-18.5%	$20.8M+6.3%	$19.5M+21.2%	$16.1M+27.9%	$12.6M+26.9%	$9.9M-32.2%	$14.7M+151.9%	$5.8M
Operating Income	$4.1M+105.8%	-$71.0M-1224.9%	-$5.4M+65.2%	-$15.4M+35.2%	-$23.8M-16.2%	-$20.5M-35.2%	-$15.2M+1.3%	-$15.4M
Interest Expense	$2.1M+2.1%	$2.0M+2.0%	$2.0M-10.3%	$2.2M+4.0%	$2.1M+187.1%	$735K-2.8%	$756K+106.6%	$366K
Income Tax	-$433K-119.7%	$2.2M+86.0%	$1.2M-92.3%	$15.4M+21858.6%	$70K+200.0%	-$70K	$0-100.0%	$177K
Net Income	-$544K-100.7%	$74.7M+2510.7%	-$3.1M+91.3%	-$35.7M-79.4%	-$19.9M-19.9%	-$16.6M+16.4%	-$19.9M-91.9%	-$10.4M
EPS (Diluted)	$-0.01-100.8%	$1.21	N/A	$-0.69-43.7%	$-0.48	N/A	N/A	N/A

ZVRA Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$178.1M+3.4%	$172.3M+49.4%	$115.3M-13.2%	$132.9M+1086.0%	$11.2M+6.7%	$10.5M
Current Assets	$86.0M-1.0%	$86.9M-6.4%	$92.8M-19.3%	$115.1M+1272.7%	$8.4M+20.2%	$7.0M
Cash & Equivalents	$33.8M-21.5%	$43.0M-34.2%	$65.5M-41.7%	$112.3M+2566.7%	$4.2M+31.0%	$3.2M
Inventory	$2.0M	$0-100.0%	$671K	N/A	N/A	N/A
Accounts Receivable	$10.2M-36.9%	$16.1M+124.3%	$7.2M+405.6%	$1.4M-41.8%	$2.4M+45.3%	$1.7M
Goodwill	$4.7M0.0%	$4.7M	$0	N/A	N/A	N/A
Total Liabilities	$138.5M+25.3%	$110.5M+174.6%	$40.2M+590.7%	$5.8M-92.5%	$77.6M-8.6%	$85.0M
Current Liabilities	$34.1M-53.8%	$73.7M+513.2%	$12.0M+184.2%	$4.2M-43.9%	$7.5M+38.8%	$5.4M
Long-Term Debt	$59.5M+1074.6%	$5.1M	N/A	N/A	$67.7M-12.5%	$77.3M
Total Equity	$39.7M-35.9%	$61.9M-17.6%	$75.1M-26.1%	$101.7M+253.1%	-$66.4M+10.8%	-$74.5M
Retained Earnings	-$505.3M-26.4%	-$399.8M-13.0%	-$353.7M-32.5%	-$267.0M-3.3%	-$258.5M-5.2%	-$245.7M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$270.1M+5.4%	$256.3M+48.4%	$172.7M-3.0%	$178.1M+23.3%	$144.4M-4.5%	$151.3M-12.2%	$172.3M+24.0%	$139.0M
Current Assets	$225.1M-0.5%	$226.3M+177.5%	$81.6M-5.2%	$86.0M+41.3%	$60.9M-3.2%	$62.9M-27.7%	$86.9M-36.5%	$137.0M
Cash & Equivalents	$54.4M+14.1%	$47.7M+27.8%	$37.3M+10.5%	$33.8M-13.9%	$39.3M-8.4%	$42.8M-0.5%	$43.0M-0.5%	$43.3M
Inventory	$1.4M+23.4%	$1.1M-56.7%	$2.6M+29.9%	$2.0M-4.1%	$2.1M-59.5%	$5.1M	$0	N/A
Accounts Receivable	N/A	N/A	N/A	$10.2M	N/A	N/A	$16.1M+420.0%	$3.1M
Goodwill	$4.7M0.0%	$4.7M0.0%	$4.7M0.0%	$4.7M0.0%	$4.7M0.0%	$4.7M0.0%	$4.7M	N/A
Total Liabilities	$137.0M-1.5%	$139.0M+5.6%	$131.7M-4.9%	$138.5M+23.7%	$111.9M+9.2%	$102.5M-7.2%	$110.5M+54.5%	$71.5M
Current Liabilities	$26.1M-9.4%	$28.8M+6.9%	$27.0M-20.8%	$34.1M+11.9%	$30.4M+1.8%	$29.9M-59.4%	$73.7M+239.5%	$21.7M
Long-Term Debt	$61.3M+1.0%	$60.7M+1.0%	$60.1M+1.0%	$59.5M+2.0%	$58.3M	N/A	$5.1M	N/A
Total Equity	$133.2M+13.6%	$117.2M+185.8%	$41.0M+3.4%	$39.7M+22.1%	$32.5M-33.5%	$48.8M-21.1%	$61.9M+0.6%	$61.5M
Retained Earnings	-$434.2M-0.1%	-$433.7M+14.7%	-$508.4M-0.6%	-$505.3M-15.8%	-$436.3M-4.8%	-$416.4M-4.2%	-$399.8M-17.8%	-$339.5M

ZVRA Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$69.7M-107.7%	-$33.5M-79.2%	-$18.7M-279.3%	$10.4M+638.4%	-$1.9M+91.8%	-$23.7M
Capital Expenditures	$0-100.0%	$296K+218.3%	$93K-8.8%	$102K+209.1%	$33K+26.9%	$26K
Free Cash Flow	-$69.7M-105.9%	-$33.8M-79.9%	-$18.8M-282.0%	$10.3M+624.2%	-$2.0M+91.7%	-$23.8M
Investing Cash Flow	-$22.2M-27.4%	-$17.4M+52.6%	-$36.7M-136.5%	-$15.5M-46942.4%	-$33K-101.0%	$3.2M
Financing Cash Flow	$82.1M+188.5%	$28.5M+240.8%	$8.4M-92.6%	$113.1M+4029.6%	$2.7M-44.5%	$4.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0-100.0%	$3.4M-27.0%	$4.7M+67.8%	$2.8M	$0	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	$4.7M+230.8%	-$3.6M+56.2%	-$8.2M+49.4%	-$16.3M+15.0%	-$19.1M-18.2%	-$16.2M0.0%	-$16.2M-249.1%	-$4.6M
Capital Expenditures	$554K+160.1%	$213K+115.2%	$99K	$0	$0	$0-100.0%	$72K-58.1%	$172K
Free Cash Flow	$4.2M+208.9%	-$3.8M+54.2%	-$8.3M+48.8%	-$16.3M+15.0%	-$19.1M-18.2%	-$16.2M+0.4%	-$16.2M-238.1%	-$4.8M
Investing Cash Flow	-$4.6M-138.3%	$11.9M+13.2%	$10.5M+292.7%	-$5.5M-4141.1%	-$129K-100.9%	$14.8M+39.8%	$10.6M+123.8%	-$44.5M
Financing Cash Flow	$6.5M+372.8%	$1.4M-14.1%	$1.6M+101.9%	$796K-94.8%	$15.3M+1159.7%	$1.2M-75.7%	$5.0M-80.9%	$26.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$0	$0	$0	$0	$0

ZVRA Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	68.6%-20.7pp	89.3%-8.5pp	97.8%+5.0pp	92.8%	N/A	22.1%
Operating Margin	-368.5%-187.8pp	-180.6%+238.3pp	-418.9%-445.9pp	27.0%+69.2pp	-42.2%+116.2pp	-158.4%
Net Margin	-446.8%-279.2pp	-167.7%+95.8pp	-263.5%-233.6pp	-29.9%+66.2pp	-96.0%+95.0pp	-191.0%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-59.2%-32.5pp	-26.7%-3.5pp	-23.2%-16.8pp	-6.4%+107.4pp	-113.8%+119.5pp	-233.4%
Current Ratio	2.53+1.3	1.18-6.5	7.72-19.5	27.20+26.1	1.11-0.2	1.28
Debt-to-Equity	1.50+1.4	0.08-0.5	0.54+0.5	0.06+1.1	-1.02+0.0	-1.04
FCF Margin	-295.0%-171.8pp	-123.2%+61.9pp	-185.1%-221.2pp	36.1%+50.9pp	-14.8%+170.2pp	-185.1%

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	95.3%+43.1pp	52.2%-41.2pp	93.4%+4.7pp	88.7%+69.0pp	19.7%-75.2pp	94.9%+10.4pp	84.5%-10.5pp	95.0%
Operating Margin	15.9%+290.4pp	-274.5%-248.2pp	-26.3%+101.7pp	-128.0%+406.8pp	-534.8%+63.3pp	-598.1%-480.8pp	-117.3%+413.4pp	-530.7%
Net Margin	-2.1%-290.8pp	288.7%+303.9pp	-15.2%+281.6pp	-296.8%+151.1pp	-447.9%+37.5pp	-485.3%-331.4pp	-154.0%+204.1pp	-358.1%
Return on Equity	N/A	63.7%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-0.2%-29.3pp	29.1%+30.9pp	-1.8%+18.3pp	-20.1%-6.3pp	-13.8%-2.8pp	-11.0%+0.6pp	-11.5%-4.1pp	-7.5%
Current Ratio	8.62+0.8	7.85+4.8	3.02+0.5	2.53+0.5	2.00-0.1	2.10+0.9	1.18-5.1	6.31
Debt-to-Equity	0.46-0.1	0.52-0.9	1.46-0.0	1.50-0.3	1.80-0.3	2.10+2.0	0.08-1.1	1.16
FCF Margin	15.9%+30.7pp	-14.7%+26.0pp	-40.8%+94.1pp	-134.9%+294.6pp	-429.5%+42.5pp	-472.0%-346.3pp	-125.6%+40.2pp	-165.8%

Similar Companies

Prothena PRTA

$482.3M

Erasca, Inc. ERAS

$3.7B

Astria Therapeutics Inc ATXS

$718.1M

Lexicon Pharmaceuticals Inc LXRX

$547.4M

Atyr Pharma Inc ATYR

$87.6M

Frequently Asked Questions

What is Zevra Therapeutics Inc's annual revenue?

Zevra Therapeutics Inc (ZVRA) reported $23.6M in total revenue for fiscal year 2024. This represents a -14.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Zevra Therapeutics Inc's revenue growing?

Zevra Therapeutics Inc (ZVRA) revenue declined by 14% year-over-year, from $27.5M to $23.6M in fiscal year 2024.

Is Zevra Therapeutics Inc profitable?

No, Zevra Therapeutics Inc (ZVRA) reported a net income of -$105.5M in fiscal year 2024, with a net profit margin of -446.8%.

What is Zevra Therapeutics Inc's EBITDA?

Zevra Therapeutics Inc (ZVRA) had EBITDA of -$80.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Zevra Therapeutics Inc have?

As of fiscal year 2024, Zevra Therapeutics Inc (ZVRA) had $33.8M in cash and equivalents against $59.5M in long-term debt.

What is Zevra Therapeutics Inc's gross margin?

Zevra Therapeutics Inc (ZVRA) had a gross margin of 68.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Zevra Therapeutics Inc's operating margin?

Zevra Therapeutics Inc (ZVRA) had an operating margin of -368.5% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Zevra Therapeutics Inc's net profit margin?

Zevra Therapeutics Inc (ZVRA) had a net profit margin of -446.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Zevra Therapeutics Inc's free cash flow?

Zevra Therapeutics Inc (ZVRA) generated -$69.7M in free cash flow during fiscal year 2024. This represents a -105.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Zevra Therapeutics Inc's operating cash flow?

Zevra Therapeutics Inc (ZVRA) generated -$69.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Zevra Therapeutics Inc's total assets?

Zevra Therapeutics Inc (ZVRA) had $178.1M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Zevra Therapeutics Inc's capital expenditures?

Zevra Therapeutics Inc (ZVRA) invested $0 in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Zevra Therapeutics Inc spend on research and development?

Zevra Therapeutics Inc (ZVRA) invested $42.1M in research and development during fiscal year 2024.

How many shares does Zevra Therapeutics Inc have outstanding?

Zevra Therapeutics Inc (ZVRA) had 54M shares outstanding as of fiscal year 2024.

What is Zevra Therapeutics Inc's current ratio?

Zevra Therapeutics Inc (ZVRA) had a current ratio of 2.53 as of fiscal year 2024, which is generally considered healthy.

What is Zevra Therapeutics Inc's debt-to-equity ratio?

Zevra Therapeutics Inc (ZVRA) had a debt-to-equity ratio of 1.50 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Zevra Therapeutics Inc's return on assets (ROA)?

Zevra Therapeutics Inc (ZVRA) had a return on assets of -59.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Zevra Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Zevra Therapeutics Inc (ZVRA) had $33.8M in cash against an annual operating cash burn of $69.7M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Zevra Therapeutics Inc's Piotroski F-Score?

Zevra Therapeutics Inc (ZVRA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Zevra Therapeutics Inc's earnings high quality?

Zevra Therapeutics Inc (ZVRA) has an earnings quality ratio of 0.66x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Zevra Therapeutics Inc cover its interest payments?

Zevra Therapeutics Inc (ZVRA) has an interest coverage ratio of -11.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Zevra Therapeutics Inc?

Zevra Therapeutics Inc (ZVRA) scores 27 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.